Author:
Feng Yutian,Meshaw Rebecca L.,Finch Sean W.,Zheng Yongxiang,Minn Il,Vaidyanathan Ganesan,Pomper Martin G.,Zalutsky Michael R.
Funder
National Institutes of Health
National Cancer Institute
Reference43 articles.
1. Fallah J, Agrawal S, Gittleman H, Fiero MH, Subramaniam S, John C, et al. FDA approval summary: lutetium [177Lu]vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2023:OF1-OF7.
2. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control;Kratochwil;J Nucl Med,2018
3. Preclinical evaluation of 213Bi-and 225Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer;Banerjee;J Nucl Med,2021
4. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding;Kratochwil;J Nucl Med,2017
5. Targeted alpha-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine;Chakravarty;Am J Nucl Med Mol I,2018
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献